Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept
February 14, 2024 07:00 ET
|
Opthea Limited
COAST trial is evaluating the superiority of sozinibercept combined with EYLEA® (aflibercept) over EYLEA alone in wet AMD Enrollment of second pivotal trial (ShORe) to complete in calendar Q2 2024 ...
Global Polymerase Chain Reaction Market Size To Worth USD 26.04 Billion By 2033 | CAGR of 7.8%
February 13, 2024 08:00 ET
|
SPHERICAL INSIGHTS LLP
New York, United States , Feb. 13, 2024 (GLOBE NEWSWIRE) -- The Global Polymerase Chain Reaction Market Size is to Grow from USD 12.21 Billion in 2023 to USD 26.04 Billion by 2033, at a Compound...
Regenerative Medicine Market is Expected to Reach $49.0 Billion | MarketsandMarkets™
February 13, 2024 07:30 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Regenerative Medicine market in terms of revenue was estimated to be worth $16.0 billion in 2023 and is poised to reach $49.0 billion by 2028, growing at a...
Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung
February 13, 2024 07:00 ET
|
Krystal Biotech, Inc.
• FDA clears IND and Phase 1 (KYANITE-1) clinical trial expected to be initiated in 1H 2024 PITTSBURGH, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a...
Global Cell Isolation Market Size To Worth USD 13.4 Billion By 2033 | CAGR of 12.5%
February 13, 2024 05:30 ET
|
SPHERICAL INSIGHTS LLP
New York, United States , Feb. 13, 2024 (GLOBE NEWSWIRE) -- The Global Cell Isolation Market size is expected to Grow from USD 4.1 Billion in 2023 to USD 13.4 Billion by 2033, at a Compound Annual...
Amniotic Membrane Market Size & Share to Exceed USD 12.8 Billion by 2034, at CAGR of 13.60%. “Harnessing Regenerative Medicine for Tissue Repair"– By PMI
February 12, 2024 18:30 ET
|
PMI
Covina, Feb. 12, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Amniotic Membrane Market size was valued at about USD 4.0 Billion in 2024 and expected to grow at CAGR of...
Ruxoprubart (NM8074) Scores FDA Orphan Drug Designation for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment
February 12, 2024 08:30 ET
|
NovelMed Therapeutics Inc
FDA grants orphan drug designation to Ruxoprubart (NM8074) for the treatment of PNH.Ruxoprubart is an Anti-Bb antibody that selectively blocks the alternative pathway while maintaining the intactness...
ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)
February 12, 2024 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA , Feb. 12, 2024 (GLOBE NEWSWIRE) -- The Company holds a U.S. patent for the same treatment via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage...
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
February 12, 2024 08:00 ET
|
4D Molecular Therapeutics, Inc.
4D-310 demonstrated clinically meaningful cardiac endpoint improvements through 12-24 months in contractility (echocardiography), peak VO2 (cardiopulmonary exercise testing) and/or cardiac quality of...
Contract Research Organization Services (CROs) Market is Expected to Reach $129.8 Billion | MarketsandMarkets™
February 12, 2024 07:30 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Contract Research Organization Services (CROs) market in terms of revenue was estimated to be worth $82.0 billion in 2024 and is poised to reach $129.8...